1. Sotatercept targets activin signaling to reverse vascular remodeling in PAH.
2. Participants received the drug every 21 days for a year.
3. Improvements in 6MWD and NT-proBNP levels were significant.
4. 90.8% experienced treatment-emergent adverse events, primarily mild.
5. Study involved 426 patients and is ongoing, planned for up to 7 years.
6. Serious TEAEs occurred in 30.3% of participants.
7. Most adverse events managed with dose adjustments.

Source: ERS Publications